

Indonesia donates \$1 M to further CEPI's vaccine research

29 December 2020 | News

Aims to strengthen national health resilience and capacity to respond to future pandemics as a foundation for regional and global health resilience



The Government of Indonesia and Norway based CEPI, the Coalition for Epidemic Preparedness Innovations, have announced that Indonesia will provide a financial contribution of \$1 million to support CEPI's efforts to advance the development of vaccines against epidemic diseases.

The commitment was formally made at a virtual signing ceremony by Secretary General of the Indonesian Ministry of Foreign Affairs, Mr. Cecep Herawan and CEO of CEPI, Dr. Richard Hatchett, and witnessed by the Indonesia's Minister of Foreign Affairs, Her Excellency Retno L.P. Marsudi. The signing marked Indonesia's membership in the coalition.

Provided through the Ministry of Foreign Affairs, Indonesia's financial contribution will further vaccine programmes against Nipah, alongside CEPI's other target diseases – Lassa Fever, Middle Eastern Respiratory Syndrome (MERS), Rift Valley fever, Chikungunya, and Ebola – and the advancement of [rapid-response platforms](#) to quickly develop vaccines in response to an unknown threat (known as 'Disease X'). The overall collective goal of the partnership is to strengthen national and global health security and the world's ability to prepare and combat future disease threats.

Indonesia has been actively participated in fostering global solidarity and international cooperation for COVID-19 mitigation. Indonesia is part of [COVAX](#), the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator co-led by CEPI, Gavi, the Vaccine Alliance and the World Health Organization (WHO) to develop, manufacture and equitably deliver up to 2 billion doses of vaccine by the end of 2021 and end the acute phase of the pandemic. To date, a total of 187 economies, representing over 90% of the global population, are engaged in the initiative, with Indonesia eligible to receive vaccines for 3 to 20% populations through the COVAX Advance Market Commitment (AMC), a financing mechanism of COVAX that will support access to safe and effective COVID-19 vaccines.